Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
March 21, 2018
Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on Amyloidosis
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (FBIO) Company developing treatments for rare and life-threatening diseases, ...
March 20, 2018
AC Immune reports full-year 2017 financial results - successful first year as a public company
Lausanne, Switzerland, March 20, 2018 - AC Immune SA (ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today ...
March 20, 2018
DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER
CUPERTINO, Calif., March 20, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that its licensee, Pain Therapeutics (PTIE), reported yesterday that the U.S. Food and Drug ...
March 20, 2018
Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference
AUSTIN, Texas, March 20, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
March 20, 2018
Rockwell Medical Announces Triferic Presentations at the 2018 Asia Pacific Congress of Nephrology
WIXOM, Mich., March 20, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), announced today that four Triferic abstracts have been selected for presentation at the ...
March 20, 2018
Zealand Pharma's first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objective
Copenhagen, March 20, 2018 - Zealand Pharma A/S ("Zealand") announces that the primary and key secondary objectives of the first multinational Phase 3 clinical trial of ...
March 20, 2018
BIOPHYTIS files for Orphan Drug Designation for Sarconeos in Duchenne Muscular Dystrophy (DMD)
PARIS, March 20, 2018 (GLOBE NEWSWIRE) --  BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related degenerative diseases, ...
March 20, 2018
Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
SAN DIEGO, March 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that it intends to offer and sell, subject to market and other conditions, ...
March 20, 2018
Altimmune to Announce Year End 2017 Financial Results on March 29
GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the ...
March 20, 2018
Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases
DUBLIN, Ireland, March 20, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of ...
March 19, 2018
OSE Immunotherapeutics to Present New Data on OSE-172 at American Association for Cancer Research Annual Meeting 2018, in Chicago, April 14-18
NANTES, France, March 19, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) today announced that the Company will present ex-vivo and preclinical data in ...
March 19, 2018
Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis
SAN DIEGO, March 19, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), today announced positive topline Phase 2 results from the OASIS trial for etrasimod, an investigational, ...
March 19, 2018
Molecular Templates to Present at the Oppenheimer 28th Annual Healthcare Conference
AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered ...
March 19, 2018
AIT Therapeutics Reports Year End 2017 Financial Results
NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide ...
March 19, 2018
Cormedix Inc. Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Business Update
BERKELEY HEIGHTS, NJ / ACCESSWIRE / March 19, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
March 19, 2018
Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
SANTA MONICA, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today ...
March 19, 2018
Brainsway Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
HACKENSACK, N.J., March 19, 2018 (GLOBE NEWSWIRE) -- Brainsway Ltd. (BRIN.TA), a leader in the advanced non-invasive treatment of brain disorders, today announced the Company’s ...
March 15, 2018
BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum
HACKENSACK, N.J. and PETACH TIKVAH, Israel, March 15, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today ...
March 15, 2018
OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
NANTES, France, March 15, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics(ISIN:FR0012127173) (Mnémo:OSE), today announces that the Company has received a positive opinion in Europe through the ...
March 15, 2018
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
LIVONIA, Mich., March 15, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
Page 57 of 117